Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Adoptive T cell therapy (ACT) has yielded high response rates in melanoma, however 50–60% of patients experience no clinical benefit. Here, the authors identify predictive biomarkers, high non-synonymous mutation and high expressed neoantigen load, that associate with clinical benefit in ACT melanom...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/63635278846d435eabbeb4ee5d2c1d15 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|